MNG688
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.637
- ANDROGEN_RESPONSE+0.483
- TGF_BETA_SIGNALING+0.454
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.445
- MTORC1_SIGNALING+0.428
- IL6_JAK_STAT3_SIGNALING+0.425
- INFLAMMATORY_RESPONSE+0.422
- HYPOXIA+0.419
- PROTEIN_SECRETION+0.395
- APOPTOSIS+0.359
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.098
- E2F_TARGETS-0.088
- DNA_REPAIR-0.074
- NOTCH_SIGNALING-0.070
- HEDGEHOG_SIGNALING-0.043
- PANCREAS_BETA_CELLS-0.027
- APICAL_SURFACE+0.045
- WNT_BETA_CATENIN_SIGNALING+0.049
- APICAL_JUNCTION+0.080
- PEROXISOME+0.091
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EPT0508 | EPN | Posterior Fossa EPN | 0.894 |
| 2 | TCGA-51-4079-01A-01R-1100-07 | — | cohortSQ2 | 0.874 |
| 3 | TCGA-ZF-AA56-01A-31R-A39I-07 | — | — | 0.854 |
| 4 | 20060039.TNBC | — | C | 0.851 |
| 5 | TCGA-52-7811-01A-11R-2125-07 | — | cohortSQ1 | 0.848 |
| 6 | MNG202 | — | — | 0.846 |
| 7 | R275 | — | — | 0.842 |
| 8 | BS_2YCJV2VV | low-grade glioma | — | 0.837 |
| 9 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.835 |
| 10 | TCGA-BT-A0YX-01A-11R-A10U-07 | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.637 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.483 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.454 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.445 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.428 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.425 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.422 | Idelalisib | — uncovered |
| HYPOXIA | 0.419 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.395 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.359 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.359 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.357 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.350 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.347 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.334 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.327 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.321 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.315 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.313 | Idelalisib | — uncovered |